Literature DB >> 7477973

Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis.

L A Stone1, P S Albert, M E Smith, C DeCarli, M R Armstrong, D E McFarlin, J A Frank, H F McFarland.   

Abstract

MRI is a sensitive technique for assessing disease activity in MS. Diseased white matter (WM) can be identified on T2-weighted images, and active disease is reflected by abnormalities in the blood-brain barrier (BBB) shown on T1-weighted images after administration of paramagnetic contrast agents. Active disease may be demonstrated by contrast-enhanced MRI in patients with early, mild relapsing-remitting (RR) MS even during periods of clinical stability, which indicates that MS is an active process even during the early phase of the illness. To examine the amount of abnormal WM at frequent intervals over time, we studied seven mildly affected RRMS patients, all of whom had frequent contrast-enhancing lesions. These RRMS patients were imaged monthly for 26 to 36 months at 1.5 tesla; the area of abnormal increased WM signal was calculated by image-processing software that utilizes both the T2- and T1-weighted images. All patients showed fluctuations over time in amount of abnormal WM signal, which reflected factors such as the amount of BBB breakdown (measured by number or area of enhancing lesions) and measurement error. All seven RRMS patients, however, showed an overall increase in abnormal WM. Because of the fluctuations between individual measurements, the increase was most accurately reflected when the mean of the first 6 months' measurements was compared with the mean of the final 6 months' measurements, or when a linear regression model was applied.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477973     DOI: 10.1212/wnl.45.10.1808

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

2.  Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis?

Authors:  M P Wattjes; M Harzheim; C K Kuhl; J Gieseke; S Schmidt; L Klotz; T Klockgether; H H Schild; G G Lutterbey
Journal:  AJNR Am J Neuroradiol       Date:  2006-09       Impact factor: 3.825

Review 3.  Evidence from clinical trials: can we do better?

Authors:  Andrew D Siderowf
Journal:  NeuroRx       Date:  2004-07

4.  Supervised automatic procedure to identify new lesions in brain MR longitudinal studies of patients with multiple sclerosis.

Authors:  R C Parodi; F Levrero; M P Sormani; A Pilot; G L Mancardi; A Aliprandi; F Sardanelli
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

Review 5.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

6.  Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells.

Authors:  A E Lovett-Racke; J L Trotter; J Lauber; P J Perrin; C H June; M K Racke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

7.  Cerebellar susceptibility to experimental autoimmune encephalomyelitis in SJL/J mice: potential interaction of immunology with vascular anatomy.

Authors:  James R Tonra
Journal:  Cerebellum       Date:  2002 Jan-Mar       Impact factor: 3.847

8.  Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.

Authors:  Bastiaan Moraal; Dominik S Meier; Peter A Poppe; Jeroen J G Geurts; Hugo Vrenken; William M A Jonker; Dirk L Knol; Ronald A van Schijndel; Petra J W Pouwels; Christoph Pohl; Lars Bauer; Rupert Sandbrink; Charles R G Guttmann; Frederik Barkhof
Journal:  Radiology       Date:  2008-11-26       Impact factor: 11.105

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.